DEV Community: Jordy Stravers

CRO Recruitment in the Netherlands: Staffing Contract Research Organizations

Jordy Stravers — Tue, 11 Aug 2026 11:35:11 +0000

A CRO, or Contract Research Organization, provides outsourced clinical research services to pharmaceutical and biotech companies, covering everything from study set-up and site management to data analysis and regulatory submissions. Staffing a CRO successfully takes people who combine scientific grounding with project management skill and a genuine command of GCP.

Profiles CROs Recruit Most Often

Clinical Research Associates at junior, senior and lead level form the backbone of most CRO teams, alongside Clinical Trial Managers, clinical data managers and biostatisticians, regulatory affairs specialists for clinical dossiers, site management organization staff, medical monitors and medical writers, and project managers dedicated to clinical research delivery.

The Dutch CRO Market

The Netherlands hosts a prominent CRO presence, including local offices of IQVIA, Syneos Health, PRA Health Sciences and Labcorp Drug Development, plus a number of homegrown Dutch CROs. Demand keeps climbing as sponsors run more decentralized and adaptive trial designs that require denser, more specialized monitoring teams.

What Makes CRO Hiring Hard

CRO work is inherently client facing and deadline driven: a CRA who is technically excellent but cannot manage sponsor expectations under a tight monitoring visit schedule will still struggle in the role. The best CRO hires tend to combine solid GCP fundamentals with the composure to manage multiple sites, multiple sponsors, and shifting trial timelines at once.

This article is adapted from the original piece on the SIRE Life Sciences blog.

CDMO Recruitment in the Netherlands: Finding Talent for Contract Manufacturing

Jordy Stravers — Tue, 11 Aug 2026 11:33:21 +0000

A CDMO, or Contract Development and Manufacturing Organization, provides outsourced drug development and manufacturing services to pharmaceutical companies. These organizations combine process optimization, GMP manufacturing, and technology transfer expertise, which creates a distinct set of hiring requirements compared with product companies.

Roles CDMOs Need Most

Process development scientists working upstream and downstream, GMP manufacturing supervisors and operators, technology transfer managers, quality assurance and QC analysts, client project managers, regulatory CMC specialists, and automation or equipment engineers all sit on the typical CDMO org chart.

The Dutch CDMO Landscape

The Netherlands has built a strong CDMO sector, anchored by players such as FUJIFILM Diosynth Biotechnologies in Tilburg, Rentschler Biopharma, and Bilthoven Biologicals (Intravacc), alongside a number of smaller specialist CMOs. Continued growth in biologics and advanced therapies keeps expanding the talent gap in this space.

Why CDMO Recruitment Is Different

Because a CDMO's business is built entirely on serving multiple clients' regulatory and manufacturing needs at once, hiring managers look for candidates who are comfortable switching context between projects, documenting everything to audit-ready standard, and communicating directly with client quality and regulatory teams, not just their own. That combination of technical depth and client-facing rigor is harder to find than pure manufacturing experience alone.

This article is adapted from the original piece on the SIRE Life Sciences blog.

Why Digital Transformation in Life Sciences Fails Without a People Strategy

Jordy Stravers — Mon, 10 Aug 2026 12:39:43 +0000

Digital transformation is no longer optional for biotech, pharma, medtech, or diagnostics companies in the Netherlands. The pressure is the same everywhere: move faster, use data better, and scale innovation without compromising quality. Yet despite record investment in platforms, AI tools, and digital infrastructure, many transformation programs quietly stall, usually not because the technology fails, but because the organization around it never actually changes.

Why Digital Transformation So Often Falls Short

Most digital transformation initiatives do not collapse at launch. They fail six to eighteen months later, once the initial excitement fades and the platform is expected to run as part of daily operations. In a regulated environment, digital initiatives constantly collide with existing tensions: scientific precision versus digital experimentation, risk mitigation versus speed to value, and individual expertise versus cross-functional execution. None of these tensions are inherently bad, they are actually the foundation of a well-run life sciences organization. But without a deliberate people strategy sitting alongside the technology rollout, transformation feels like disruption rather than progress. The platform works exactly as designed. The real problem is that no one feels responsible for using it.

What a People Strategy Actually Means

There is a common misunderstanding worth clearing up here. A people strategy is not a communication plan, a training catalogue, or a change management checklist, those are support tools, not a strategy. A real people strategy is a deliberate redesign of how work actually gets done. In practice that means clarifying who owns digital outcomes and not just delivery, how decisions get made and escalated, what leaders reward versus what they quietly ignore, and whether existing roles still reflect the new way of working.

The Recruitment Angle Most Companies Miss

This is exactly where workforce planning intersects with digital strategy. Rolling out new platforms and AI-supported processes only works if the organization also hires and develops people who can operate in that redesigned structure, not just people who can use the software. Specialist life sciences recruitment increasingly needs to account for this: quality, regulatory, and manufacturing professionals who are comfortable owning outcomes in a more digital, cross-functional environment.

This article is adapted from the original piece on the SIRE Life Sciences blog: https://www.sire-search.com/digital-transformation-fails-without-people-strategy/

AI in Life Sciences Talent Delivery: Opportunities and Limits in the Netherlands

Jordy Stravers — Mon, 10 Aug 2026 12:38:25 +0000

Artificial intelligence is starting to reshape how pharmaceutical, biotech, and medtech companies in the Netherlands find, assess, and deploy specialist talent. For an industry that has always relied on deep technical vetting, this shift raises a fair question: can AI actually speed up regulated hiring without cutting corners on quality?

Where AI Is Already Changing Life Sciences Recruitment

Traditional life sciences recruitment is slow by nature. Manually screening candidates for niche GMP, regulatory, or clinical expertise takes real time, and the pool of genuinely qualified people is small. AI tools now help recruiters search larger networks faster, recognize patterns in experience and qualifications, and accelerate that first screening round. Predictive matching algorithms can also flag professionals who are not actively job hunting but would be open to the right opportunity, something that used to depend entirely on a recruiter's personal network.

Why Human Judgment Still Decides the Outcome

None of this replaces the human side of the process. Interpreting a deviation report, communicating with a regulator, or making a critical quality decision is still work that requires a person with real domain expertise. If anything, professionals who understand both their field and how AI tools are used in it, for example in drug discovery, predictive quality analytics, or AI-assisted clinical data analysis, are becoming more valuable, not less.

How SIRE Life Sciences Approaches AI-Driven Talent Delivery

At SIRE Life Sciences, AI is used to combine faster matching with sector-specific judgment rather than to replace it. In practice, this supports building a candidate longlist within roughly 48 hours, proactively identifying passive candidates who fit a specific profile, and forecasting how available certain specialist profiles are likely to be in the Dutch market. The technology speeds up the search; the placement decision itself still rests with experienced life sciences recruiters.

For life sciences organizations in the Netherlands, the practical lesson is that AI works best as a way to widen and speed up the search, not as a substitute for the expertise needed to judge who is actually the right fit.

This article is adapted from the original piece on the SIRE Life Sciences blog: https://www.sire-search.com/ai-life-sciences-talent-delivery-nederland/

Medical Science Liaison (MSL) Careers in the Netherlands: Role, Qualifications, and Salary

Jordy Stravers — Mon, 10 Aug 2026 07:50:05 +0000

A Medical Science Liaison (MSL) is a scientific expert who represents a pharmaceutical company in deep, non-commercial dialogue with Key Opinion Leaders (KOLs), physicians, and researchers about new and existing medicines. It is one of the more scientifically demanding roles in pharma, sitting between R&D, medical affairs, and the clinical community.

What an MSL Actually Does

MSLs build long-term relationships with KOLs and medical experts, share clinical data and scientific information in response to unsolicited requests, and support investigator-initiated trials (IITs). They also contribute to medical strategy and advisory boards, and respond to medical-scientific questions from healthcare professionals in the field.

Qualifications for the Role

MSLs typically hold a PhD, PharmD, MD, or another advanced degree in pharmacy, medicine, or biomedical sciences. Strong communication skills and genuine scientific credibility with clinicians are essential, since the role depends entirely on being taken seriously as a peer by physicians and researchers.

MSL Salaries in the Netherlands

MSLs in the Netherlands typically earn between €5,000 and €9,000 gross per month, depending on seniority and therapeutic area. Oncology, rare disease, and cell and gene therapy specializations tend to command the higher end of that range.

Hiring MSLs Through SIRE® Life Sciences

SIRE® Life Sciences maintains a specialized network of MSL professionals with experience in oncology, cardiology, neurology, and rare diseases for pharma and biotech companies across the Netherlands. For related career paths in the same regulatory and clinical ecosystem, see our guides to Regulatory Affairs Careers in Life Sciences and Pharma Careers in the Netherlands.

FAQ

What is the difference between an MSL and a sales representative?
MSLs operate outside the commercial sphere and focus on scientific education, while sales reps pursue commercial objectives.

Can a physician become an MSL?
Yes, physicians are highly valued MSL candidates because of the clinical credibility they bring when engaging with KOLs.

This article is adapted from the original piece on the SIRE Life Sciences blog.

CRO Recruitment in the Netherlands: Building Teams for Contract Research Organizations

Jordy Stravers — Mon, 10 Aug 2026 07:48:17 +0000

Contract Research Organizations (CROs) provide outsourced clinical research services to pharmaceutical and biotech companies, covering everything from study design and site management to data analysis and regulatory submissions. Building a CRO team requires professionals who combine scientific expertise, project management skill, and deep knowledge of Good Clinical Practice (GCP).

Profiles CROs Need Most

Contract research organizations in the Netherlands recruit across a specific set of roles. Clinical Research Associates (CRAs) at junior, senior, and lead levels form the backbone of most CRO teams, alongside Clinical Trial Managers who oversee study execution end to end. Clinical Data Managers and biostatisticians turn trial data into submission-ready evidence, while regulatory affairs specialists prepare the clinical dossiers that keep studies compliant across jurisdictions. Site Management Organization staff, medical monitors, medical writers, and clinical project managers round out the profiles that keep a CRO's pipeline moving.

A Strong CRO Sector in the Netherlands

The Netherlands hosts a prominent CRO sector, with operations from IQVIA, Syneos Health, PRA Health Sciences, Labcorp Drug Development, and several Dutch-founded CROs. Amsterdam, Utrecht, and Leiden are the main hubs. The country's appeal as a CRO location comes down to a multilingual workforce, high ICH/GCP standards, and access to diverse patient populations for clinical trials.

Why SIRE® Life Sciences for CRO Recruitment

SIRE® Life Sciences maintains a large network of clinical research professionals across the Netherlands and understands the fast-paced, deadline-driven environment CROs operate in. We place CRAs, Clinical Trial Managers, and data management professionals into both permanent roles and project-based secondment, matching candidates to the specific therapeutic areas and study phases our CRO clients are running. For related recruitment challenges in outsourced manufacturing, see our guide to CDMO Recruitment in the Netherlands, and for a broader view of the market, our Complete Guide to Life Science Recruitment in the Netherlands.

FAQ

What are the requirements for a CRA role at a CRO?
Typically a bachelor's or master's degree in life sciences, GCP certification, and willingness to travel for site visits.

Is there demand for junior CRAs at CROs?
Yes, CROs often offer strong entry points for early-career professionals in clinical research through structured trainee programs.

This article is adapted from the original piece on the SIRE Life Sciences blog.

Amsterdam Science Park: Innovation and Career Opportunities in Dutch Life Sciences

Jordy Stravers — Fri, 07 Aug 2026 11:43:50 +0000

Amsterdam Science Park, located in the eastern part of the Dutch capital, has grown into an international hub for scientific research, startups and established companies shaping the future of technology and life sciences. It brings together education, entrepreneurship and advanced research facilities in one dynamic district.

From Watergraafsmeer to a National Innovation District

The area now known as Amsterdam Science Park was originally part of the Watergraafsmeer polder, and carried that name for decades. Over the years the site was developed and expanded specifically to house scientific institutions and innovative companies, and the shift to the "Science Park" name reflects that deliberate focus on research, science and technology. Amsterdam Science Park railway station now makes the park one of the best-connected innovation districts in the country, with direct train access for the students, researchers and professionals who work there daily.

Education and Research Side by Side

The study programs based at the park cover a wide range of disciplines, from physics and chemistry to mathematics, computer science and life sciences. The Faculty of Science (FNWI) of the University of Amsterdam is based here, combining high-quality teaching with cutting-edge research, alongside several other knowledge institutions that add to the breadth of disciplines on offer. Students benefit not only from academic instruction but also from close proximity to research institutes, laboratories and innovative companies, giving them practical experience alongside theory.

A Growing Business and Innovation Ecosystem

Amsterdam Science Park is home to a wide variety of organizations, spanning ICT, biotech and sustainability, from university spin-offs that grow into scale-ups to multinationals opening new R&D departments. This proximity between science and business creates constant knowledge exchange and a steady stream of new ideas. Facilities on site are geared toward this mix of academic and commercial activity, with good parking, cycling and public transport connections for everyone working or studying there.

Career Opportunities for Life Sciences Talent

For life sciences professionals, Amsterdam Science Park offers a growing number of opportunities across biotechnology, pharmaceuticals and IT, often directly linked to the many organizations based in and around the district. SIRE® Life Sciences works with candidates and employers connected to this ecosystem and to similar clusters across the Netherlands.

If you want to compare Amsterdam's ecosystem with the country's largest life sciences cluster, see our earlier article on Leiden Bio Science Park: The Life Sciences Hub of the Netherlands, or read about our own move to BioPartner 1 on the Leiden Bio Science Park.

FAQ

What is Amsterdam Science Park?
A district in eastern Amsterdam where education, research and entrepreneurship come together, home to university faculties, research institutes and companies in IT, biotech and sustainability.

What was Amsterdam Science Park called before?
The area was originally known by the name of the polder it sits in, Watergraafsmeer, before being redeveloped and renamed to reflect its focus on science and technology.

Is Amsterdam Science Park easy to reach by public transport?
Yes, Amsterdam Science Park has its own railway station with direct connections, making it easily accessible for students and professionals.

Read the original Dutch article on the SIRE® Life Sciences website: Amsterdam Science Park: Innovatie, Onderzoek en Samenwerking

SIRE® Life Sciences Relocates to BioPartner 1 on the Leiden Bio Science Park

Jordy Stravers — Fri, 07 Aug 2026 11:41:53 +0000

SIRE® Life Sciences, a specialist recruitment, secondment, project management and consultancy firm for the Dutch life sciences sector, has relocated its office to BioPartner 1, right in the heart of the Leiden Bio Science Park (LBSP). The new address is J.H. Oortweg 21, 2333 CH Leiden.

A New Address in the Middle of the Action

BioPartner 1 is the flagship building of BioPartner Leiden, a non-profit foundation that has supported life sciences startups and scale-ups since 1984 (originally founded as the Academisch Bedrijven Centrum). In 2007 it merged with the Life Sciences Incubator Leiden to form the current BioPartner foundation. The building is also a well-known venue for the monthly Life Sciences Café, one of the region's most active networking events for pharma, biotech and medtech professionals.

The Five BioPartner Buildings

BioPartner's portfolio consists of five properties across Leiden and Oegstgeest:

BioPartner 1 — J.H. Oortweg 21, 2333 CH Leiden (SIRE's new home)
BioPartner 2 — J.H. Oortweg 21, 2333 CH Leiden
BioPartner 3 — Galileïweg 8, 2333 BD Leiden
BioPartner 4 — Robert Boyleweg 4, 2333 CG Leiden
BioPartner 5 — De Limes 7, 2342 DH Oegstgeest

Together, these buildings offer flexible lab space, offices and incubator facilities to hundreds of life sciences companies.

Why the Leiden Bio Science Park Matters

Since its founding in 1984, the Leiden Bio Science Park has grown into the largest and most complete life sciences ecosystem in the Netherlands, and one of the leading clusters in Europe. It brings fundamental research, clinical development and large-scale manufacturing together in one location, in close collaboration with Leiden University and the Leiden University Medical Center (LUMC). Hundreds of organizations are based on or around the park, from academic institutes such as the Hubrecht Institute and the Netherlands Cancer Institute to international players like Janssen, Thermo Fisher, Bio-Techne and Galapagos.

For a deeper look at the park itself, see our earlier piece: Leiden Bio Science Park: The Life Sciences Hub of the Netherlands.

What This Means for Clients and Candidates

Being based inside BioPartner 1 puts SIRE® Life Sciences literally among the companies, start-ups and knowledge institutions it serves every day as a specialist in life sciences recruitment, secondment, project management and consultancy:

Shorter lines with companies on the Leiden Bio Science Park looking for Regulatory Affairs, Quality Assurance, GMP, clinical research and biotech professionals
Direct access to networking events such as the Life Sciences Café
Easy, low-threshold introductory meetings for candidates working on or near the park
Closer collaboration with partners across pharma, biotech and medical devices

FAQ

Where is SIRE® Life Sciences' new office located?
BioPartner 1, J.H. Oortweg 21, 2333 CH Leiden, on the Leiden Bio Science Park.

What is the Leiden Bio Science Park?
The largest life sciences cluster in the Netherlands, where research, education and industry come together around Leiden University and the LUMC.

What are the BioPartner buildings?
Five buildings (BioPartner 1 through 5) on and around the Leiden Bio Science Park that provide affordable workspace and facilities to life sciences start-ups and scale-ups.

Read the full announcement on the SIRE® Life Sciences website: SIRE® Life Sciences Verhuisd naar BioPartner 1

CDMO Recruitment in the Netherlands: Hiring Talent for Contract Manufacturing

Jordy Stravers — Thu, 06 Aug 2026 15:44:20 +0000

Contract Development and Manufacturing Organizations occupy a unique spot in the life sciences ecosystem: they carry the technical weight of drug production without owning the molecule, and that changes what a good hire actually looks like.

What a CDMO actually does

A CDMO (Contract Development and Manufacturing Organization) provides outsourced development and manufacturing services to pharmaceutical companies. Unlike a straightforward CMO, which only offers production capacity, a CDMO also delivers development work such as process optimization, formulation, and analytical development, alongside GMP manufacturing itself.

The profiles CDMOs need most

Process development scientists (upstream and downstream)
GMP manufacturing supervisors and operators
Technology transfer managers
Quality assurance and QC analysts
Client-facing project managers
Regulatory CMC specialists
Automation and equipment engineers

Where the Dutch CDMO sector is concentrated

The Netherlands has built a genuinely strong CDMO base, anchored by players such as FUJIFILM Diosynth Biotechnologies in Tilburg, Rentschler Biopharma, and Bilthoven Biologicals (Intravacc), alongside a longer tail of smaller CDMOs and CMOs. The continued growth of biologics and ATMPs is pushing demand for specialized CDMO talent higher every year, echoing the same pressures we described in Technology Transfer in Pharma: Why Specialized Consultancy Matters.

Why CDMO hiring is different from typical pharma recruitment

CDMO roles sit at the intersection of technical skill, quality rigor, and client relationship management, since staff are effectively delivering a service to an external sponsor rather than working on a single, internally owned product. That mix of GMP depth and client-facing fluency is exactly why CDMO vacancies often take longer to fill than equivalent roles inside a traditional manufacturer, a dynamic also visible across the broader biotech careers landscape in the Netherlands.

Working with SIRE on CDMO recruitment

SIRE Life Sciences has deep familiarity with the CDMO sector and understands the blend of technical, quality, and client-facing skills CDMO professionals need. We supply qualified candidates for both permanent and temporary roles.

FAQ

What is the difference between a CMO and a CDMO? A CMO offers only manufacturing capacity; a CDMO also provides development services such as process development, formulation, and analytical development.

What GMP knowledge is required? Depending on the product type, familiarity with EU GMP Annex 1, Annex 2, Annex 13 (ATMPs), and ICH Q7 (API manufacturing) is typically expected.

This article is adapted from SIRE Life Sciences' original article, CDMO Recruitment Nederland: Specialist in Contract Manufacturing Talent

What Is a Qualified Person (QP) in Pharma? Role, Requirements, and Salary

Jordy Stravers — Thu, 06 Aug 2026 15:42:29 +0000

In European pharmaceutical manufacturing, no batch of medicine reaches the market without one specific signature: that of the Qualified Person. It is a role defined in law, carries personal liability, and sits at the very end of the production chain as the last checkpoint before release.

What does a Qualified Person actually do?

A Qualified Person (QP) is the individual legally authorized to certify that a batch of medicinal product has been manufactured and tested in accordance with EU GMP and the terms of the relevant marketing authorization, before it can be released for sale or clinical use. The role is established under EU Directive 2001/83/EC, Article 51, and the QP is personally accountable for every batch they certify.

In practice, a QP:

Certifies each batch prior to release for sale or clinical trial use
Confirms ongoing compliance with GMP and the site's manufacturing licence
Reviews deviations, out-of-specification results, and CAPA actions before sign-off
Acts as the primary contact for regulatory authorities during GMP inspections
Signs the batch release documentation, including the Certificate of Conformance

The qualification bar is high

Article 49 of the same directive sets out strict eligibility criteria: a university degree in pharmacy, chemistry, biochemistry, medicine, or a related discipline, combined with at least two years of practical experience in pharmaceutical manufacturing or quality control. Registration with the relevant national authority (the IGJ in the Netherlands) is also required before someone can act as QP.

Why QPs are difficult to find and expensive to hire

Because the role combines rare technical depth, legal accountability, and regulatory judgment, QPs are in short supply relative to demand. In the Netherlands, QP salaries typically range between €6,000 and €12,000 gross per month, depending on experience, scope of responsibility, and company type. For smaller biotechs or CDMOs scaling up manufacturing, hiring a permanent QP is not always the right first step; an interim QP engagement to cover an inspection or a leave of absence is often more practical.

A QP's sign-off is only as reliable as the quality system underneath it. We covered that broader culture of demonstrable reliability in how GMP compliance gets protected, and how QP roles fit into the wider QA career ladder in Quality Assurance in Life Sciences: Career Paths, Responsibilities, and Salary Benchmarks.

Working with SIRE on QP recruitment

SIRE Life Sciences maintains a specialist network of certified QPs across the Netherlands, for both permanent placements and interim coverage during inspections or leave replacement.

FAQ

Can anyone become a QP? No. Beyond the required education, practical pharma experience and registration as QP with the competent authority (the IGJ in the Netherlands) are mandatory.

Can a QP be hired on an interim basis? Yes, hiring a QP through secondment is common for temporary projects or bridging periods.

This article is adapted from SIRE Life Sciences' original article, Wat is een Qualified Person (QP) in Farma?

Quality Assurance in Pharma and Biotech: How GMP Compliance Is Safeguarded

Jordy Stravers — Thu, 06 Aug 2026 14:00:26 +0000

In pharmaceutical and biotech manufacturing, Quality Assurance (QA) is more than a department, it is a culture of demonstrable reliability that runs through every phase of product development, manufacturing, and distribution. From the earliest stages of development through to commercial release, GMP compliance is not optional; it is an absolute requirement. SIRE Life Sciences connects Dutch life sciences organizations with the QA professionals they need to meet that standard consistently.

Growing demand for QA talent in the Netherlands

The Netherlands ranks among the top five pharmaceutical manufacturing countries in Europe. With international players such as MSD, Janssen, Organon, and Astellas, alongside a growing cluster of biotech companies in Leiden, Utrecht, Amsterdam, and Eindhoven, demand for qualified QA professionals has risen sharply in recent years. At the same time, the supply of experienced QA specialists remains tight, since the combination of technical depth, regulatory knowledge, and operational insight is genuinely rare.

The QA profiles SIRE Life Sciences places

The QA landscape in the pharmaceutical industry is broad and varied. At the senior level, this includes Qualified Persons (QP) responsible for batch release under EU GMP Annex 16, Responsible Persons (RP) for GDP-certified distribution, QA Directors and Head of Quality for leadership roles, and interim Quality Management System (QMS) managers for organizations in transition or growth. This overlaps closely with the career paths we outlined in our earlier post on Quality Assurance in life sciences: career paths, responsibilities, and salary benchmarks.

At the operational level, our consultants work as QA Specialists and QA Engineers handling document management, deviation management, and CAPA processes, as QA Auditors for internal and supplier audits, as QA Analysts for trend analysis and quality data, and as Document Control Specialists for GMP documentation and change control.

GMP compliance in a shifting regulatory landscape

European GMP regulation has changed substantially in recent years. The revised Annex 1 for sterile manufacturing, tightened data integrity requirements under ALCOA+, increasing EMA attention on pharmacovigilance, and the rollout of IDMP/xEVMPD for medicine registrations are all placing new demands on QA organizations. Companies that cannot scale QA capacity quickly enough risk inspection findings, production delays, and in the worst case, batch recalls. This is closely tied to the compliance distinctions we explored in GCP vs. GDP in life sciences.

SIRE Life Sciences helps organizations mitigate this risk by supplying QA experts who are ready to contribute from day one, with a solid grasp of Dutch and European regulation and no lengthy onboarding curve.

The Qualified Person: scarce and strategic

One of the most sought-after profiles in Dutch pharma is the Qualified Person (QP). A QP is legally responsible for releasing every production batch and must personally certify that a product meets all GMP requirements, its Marketing Authorisation, and applicable legislation. Finding an available, experienced QP, particularly on an interim basis, is a major challenge for many organizations. SIRE Life Sciences maintains a dedicated network of certified QPs and Responsible Persons across the Netherlands and Belgium, available for both short-term assignments and longer-term placements.

Working with SIRE Life Sciences on QA challenges

SIRE Life Sciences offers more than recruitment or secondment. As a strategic consultancy partner, we help think through your broader QA organization: which profiles you need now, which competencies may be missing in the medium term, and how to build a resilient quality organization ready for the next inspection cycle. Our AI-driven matching identifies the right QA consultant for your specific context, taking into account sector experience, regulatory framework, and organizational culture.

This article originally appeared on the SIRE Life Sciences blog.

MSP vs. SOW in Life Sciences: Choosing the Right Workforce Model

Jordy Stravers — Thu, 06 Aug 2026 13:56:58 +0000

Life sciences leaders in the Netherlands face a recurring workforce question: should external talent be brought in through a Managed Service Provider (MSP) model, a Statement of Work (SOW) model, or some blend of the two? There is no universal answer, but understanding how each model actually functions in practice makes the decision much easier.

What an MSP model delivers

An MSP model is a governance and visibility framework for external talent. It centralizes access to specialists, creates consistency across suppliers, and improves visibility into workforce spend and activity. It tends to work best for ongoing or repeat roles, high-volume specialist hiring, and multi-site or international operations where speed and control matter most. What MSP does not do particularly well is own outcomes, it manages resources, not delivery.

What an SOW model changes

An SOW model shifts the conversation from "who do we hire" to "what outcome do we need delivered." It defines scope, deliverables, timelines, and success criteria, with responsibility for delivery sitting outside the internal team. This fits defined programs, highly specialized expertise, and transformation initiatives where internal bandwidth is limited. In the Netherlands, SOW is increasingly used for data-driven initiatives, advanced therapy programs, and complex cross-functional projects, the kind of specialist engagements we covered in our earlier piece on SOW-based projects in life sciences.

The core distinction

MSP manages inputs: people, rates, access. SOW manages outputs: results, milestones, delivery. Confusing the two is often where cost overruns, delays, and frustration creep in.

Why hybrid models are becoming the norm

Most high-performing organizations do not pick one model exclusively. MSP provides structure and governance across the workforce; SOW is reserved for delivery-critical workstreams. That combination gives control where it is needed and flexibility where it matters most. For a closer look at how SOW compares with more traditional secondment arrangements, see our related breakdown of Statement of Work vs. secondment models.

Choosing the right approach

Before deciding, bring HR, Talent Acquisition, Procurement, and business leaders into the same conversation. Ask what problem is actually being solved, where control versus accountability matters most, and how success will be measured. When those answers are clear, the right model usually becomes obvious. Sometimes that is MSP, sometimes it is SOW, and often it is a deliberate mix of both.

This article originally appeared on the SIRE Life Sciences blog.